(VIANEWS) – The Market ended the session with ERYTECH PHARMA (ERYP.PA) rising 14.74% to €1.01 on Wednesday while CAC 40 fell 0.49% to €7,361.20.
ERYTECH PHARMA’s last close was €0.88, 40.37% under its 52-week high of €1.48.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-0.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.98%.
More news about ERYTECH PHARMA (ERYP.PA).
